

# 4 Questions to....

... Kaia Palm from Protobios



PANBioRA

## **What has been most surprising for you related to your involvement in PANBioRA so far?**

The individuality of predicted antibody response to various biomaterials was an surprising fact, we have discovered in respect to the research of PANBioRA. Also, co-operation between project partners across different disciplines and long distances works perfectly in PANBioRA. With 17 partners from 10 countries, this is not self-evident and thus even more surprising. We really appreciate this fruitful cooperation.

## **What has been most challenging for you during the past two years of PANBioRA?**

The adaptation of the standard MVA protocols to immunoprofiling of biomaterials with very different physicochemical properties.

## **From your point of view: What will be the biggest impact of PANBioRA?**

Pointing a spotlight in the current problem of limited measuring and assessment of immune response in the body. From this point of view, the developed techniques provide a comprehensive solution/framework for personalised risk assessment of the imminently developed biomaterials.



## **How would you describe PANBioRA in one sentence?**

PANBioRA is an across different fields project for personalized clinical risk assessment of biomaterials.

Learn more about Protobios and their involvement in PANBioRA!



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760921

## **About Protobios:**

Protobios is an Estonian biotechnology company founded in October 2003, and is positioning itself as a developer of new diagnostic tests and also as a service provider in the field of immunome analysis.

Throughout our history, we have contributed to the development of new technologies in the field of cell biology and immunology. We will continue to maintain our focus, today and tomorrow, on novel solutions and will always be interested to learn more from others, in order to combine joint expertise that will help lead us to the next series of inventions.

Our company, in association with hospitals and technology leaders across the world, is developing ways to facilitate new innovative technologies to improve the future of molecular diagnostics – we make diagnostics easy.

## **Role in PANBioRA:**

Protobios is mainly involved in the determination of individual's antibody response to the candidate biomaterial using Mimotope Variation Analysis, allowing biomaterial risk assessment at nanoscale level. The MVA (Mimotope Variation Analysis) based antibody testing detects the recognition of a specific biomaterial by the immune system in a personalised manner. This allows for patient-specific antibody response profiles to be determined for new or existing biomaterials.

